G
ene expression profiling has the potential to refine diagnostic and prognostic accuracy in a variety of diseases. This technique has enjoyed widespread success in solid and hematologic malignancies [1] [2] [3] [4] [5] [6] [7] and may soon be used in clinical trials. Although the ability to refine diagnosis and predict patient outcome has tremendous importance in myocardial diseases, the application of gene expression profiling is in its earliest stages. Small studies offer novel insights into gene expression in failing and nonfailing hearts, 8 -13 dilated and hypertrophic cardiomyopathy, 14 and before and after ventricular assist device placement [15] [16] [17] [18] ; however, gene expression analysis has not yet been used to distinguish clinically relevant cardiovascular disease subtypes. In fact, gene expression prediction analysis for cardiomyopathies is considered controversial because of the contention that unlike tumors, there is a final common pathway independent of etiology for the progression of myocardial disease. 19 The aim of the present study was to test the hypothesis that gene expression profiling could discriminate between the 2 major forms of cardiomyopathy, ischemic (ICM) and nonischemic (NICM). We demonstrate that the methodology is highly generalizable to data obtained in different institutions and is specific to disease stage. This study establishes proof-of-principle that gene expression profiles have the potential to refine the evaluation and treatment of heart failure patients, where management decisions may vary on the basis of disease etiology. 20 -25 Our findings strongly support ongoing efforts to incorporate expression profilingbased biomarkers in determining prognosis and response to therapy in heart failure.
Methods

Patients
The study comprised 48 samples. Myocardial tissue from different disease stages was obtained (1) at left ventricular assist device (LVAD) placement or cardiac transplantation (nϭ25, end stage), (2) after LVAD support (nϭ16; post-LVAD), and (3) from prospectively collected newly diagnosed patients at endomyocardial biopsy (nϭ7; biopsy). Samples were from 2 institutions: the Johns Hopkins Hospital (nϭ34) and the University of Minnesota (nϭ14). Samples from the latter institution were collected and prepared independently, 15 and the gene expression data files were kindly provided.
Written informed consent was obtained from all patients undergoing endomyocardial biopsy for sample collection and medical chart abstraction. Myocardial tissue obtained at LVAD placement, after LVAD support, or at cardiac transplantation, however, is considered discarded tissue. Therefore, we obtained an exemption from the Johns Hopkins Institution Review Board for its collection and medical chart abstraction without written informed consent.
ICM was defined as histological evidence of ischemic injury, and all ICM patients exhibited severe coronary artery disease (Ͼ75% stenosis of the left anterior descending artery and at least one other proximal epicardial artery) and/or a documented history of myocardial infarction. 26 NICM patients had no history of myocardial infarction, revascularization, or coronary artery disease. Newly diagnosed patients were those presenting or referred to Johns Hopkins Hospital with a new diagnosis of cardiomyopathy and symptoms for 6 months or less 20 for further diagnostic evaluation, which included endomyocardial biopsy.
Prediction Analysis
Sample collection and preparation, microarray hybridization, data normalization, and quantitative polymerase chain reaction (PCR) are fully described in the Appendix in the online-only Data Supplement. To develop a gene expression profile that distinguished ICM from NICM, we used Prediction Analysis of Microarrays (PAM) 3 implemented in the R package for statistical computing (available at www.R-project.org).
A number of prediction analyses were performed ( Figure 1 ). Sixteen end-stage cardiomyopathy samples (6 ICM and 10 NICM) from Johns Hopkins Hospital formed a training set to develop the etiology prediction profile. There were 3 test sets to validate the profile: (1) the remaining 9 end-stage cardiomyopathy samples, including 7 from the University of Minnesota; (2) 16 post-LVAD samples; and (3) 7 biopsy samples.
Because the accuracy of the profile could differ on the basis of the random division of samples into training and test tests, the above analysis was repeated with 210 random partitions of the samples into a 16-sample training set and 9-sample test set to determine the overall accuracy. Each random partition identified different, overlapping sets of genes, but a 90-gene profile repeatedly minimized the cross-validation error. We applied PAM to the entire set of 25 end-stage samples to identify the 90-gene profile as the representative etiology prediction profile. The genes in the etiology prediction profile were classified by the Gene Ontology Consortium system, and the profile was visualized by hierarchical clustering and a heat map 27 that used euclidean distance with complete linkage.
Results
Patient Characteristics
All end-stage patients exhibited severely reduced ejection fraction, left ventricular dilation, elevated pulmonary arterial and wedge pressures, and reduced cardiac index (Table 1) . Compared with end-stage NICM patients, end-stage and post-LVAD ICM patients were older, and all were male. In addition, compared with end-stage NICM patients, end-stage ICM patients were all taking ACE inhibitors and less often were taking intravenous inotropes. Hemodynamic and remodeling indices were similar between end-stage ICM and NICM patients. Newly diagnosed ICM patients were older than their NICM counterparts and had better remodeling indices.
Diagnostic Accuracy
We developed an etiology prediction profile using a training set of samples that demonstrated 100% sensitivity and 100% specificity when applied to independent end-stage ICM and NICM samples. This perfect accuracy was also achieved in a test set in which the majority of samples were from an institution distinct from that used to create the prediction profile.
We assessed whether the etiology prediction profile was affected by disease stage. In post-LVAD samples, the gene expression profile correctly classified all NICM samples (nϭ13; specificity 100%) but only classified 1 of 3 ICM samples correctly (sensitivity 33%). In biopsy samples from patients with newly diagnosed cardiomyopathy, the profile again correctly classified all NICM samples (nϭ4; specificity 100%) but only classified 1 of 3 ICM samples correctly (sensitivity 33%). The overall accuracy over 210 random partitions of training and test Overall study design. Samples were first divided into training set of endstage samples from Johns Hopkins Hospital (JHH) used to develop etiology prediction profile. It then was validated by determining its sensitivity and specificity in 3 test sets: end-stage samples from University of Minnesota (UM), post-LVAD samples from both JHH and UM, and endomyocardial biopsy samples from newly diagnosed patients at JHH. Then, end-stage samples were randomly partitioned into training and test sets to identify representative etiology prediction profile and overall sensitivity and specificity.
sets was sensitivity 89% (95% CI 75% to 100%) and specificity 89% (95% CI 60% to 100%).
Effect of Clinical Characteristics
We examined the predictive accuracy of the profile in strata based on each clinical characteristic ( Table 2 ). All ICM patients were male and taking ACE inhibitors, so we could not ascertain whether the profile would apply to ICM women not taking ACE inhibitors. However, within each stratum, the sensitivity and specificity were similar, and all were comparable to the overall sensitivity and specificity.
Characterization of the Etiology Prediction Profile
In the 210 combinations of training and test set samples, the greatest accuracy was achieved with profiles that contained 90 genes. A 90-gene expression profile exhibited perfect accuracy 30% of the time. The majority of genes in the representative etiology prediction profile were involved in signal transduction, metabolism, and cell growth/maintenance ( Figure 2 ). Most were upregulated in ICM, with an average fold change of 1.9Ϯ0.9 (Table 3) .
In a hierarchical clustering algorithm, 11 of the 16 ICM samples and 30 of the 32 NICM samples formed a distinct cluster ( Figure 3 ). Whereas the biopsy samples clustered together, the samples did not cluster by pre-or post-LVAD status or by institution of origin.
Quantitative PCR
Levels of transcript for 4 genes in the prediction profile were confirmed with quantitative PCR (Figure 4) . In all 4 cases, the direction of the fold change by microarray and quantitative PCR was the same.
Discussion
The major new finding of this report is the identification of a gene expression profile that accurately distinguishes ischemic and nonischemic cardiomyopathy. The prediction profile was generalizable to samples from different laboratories and was independent of disease stage for nonischemic samples. Gene expression profiles have been successfully correlated with etiology and outcome in oncology. [1] [2] [3] [4] [5] [6] [7] There is an equal need to refine diagnostic and prognostic techniques in myocardial diseases, but advances have been restricted by limited tissue access. The findings of the present study demonstrate that gene expression profiling can accurately identify etiology in cardiovascular disease and support ongoing efforts to incorporate expression profiling-based biomarkers in determining prognosis and response to therapy. Although the main focus of the present study was proofof-principle, a gene expression profile that distinguishes ICM and NICM could provide a valuable adjunct to diagnostic imaging and metabolic tools. ICM and NICM are distinct diseases; patients with ICM have decreased survival compared with their NICM counterparts 20, 21 and respond differently to therapies. [22] [23] [24] [25] An etiology prediction profile would offer diagnostic insight, especially in patients with heart failure out of proportion to their coronary artery disease, up to 11% in one observational study. 26 Although we have demonstrated that end-stage cardiomyopathy can be accurately classified by gene expression, a more relevant prediction profile would focus on newly diagnosed patients. Therefore, we also tested the end-stage etiology prediction profile in 7 endomyocardial biopsy samples prospectively collected from patients with newly diagnosed cardiomyopathy. The profile performed perfectly in NICM, whereas only 1 of 3 ICM samples was classified correctly. This suggests that compared with NICM patients, those with ICM exhibit greater changes in gene expression as disease progresses. These results parallel those from post-LVAD patients and emphasize the need for stage-specific prediction profiles. To the best of our knowledge, this is the first evidence that microarray hybridization from endomyocardial biopsies is feasible; this success encourages future gene expression profiling studies using endomyocardial biopsies with RNA amplification.
Prior studies have shown that cardiomyopathy of different etiologies exhibits different patterns of gene expression 9, 18 ; however, neither study developed or prospectively validated a gene expression prediction profile. In fact, one study comparing the gene expression of ICM and NICM found no differentially expressed genes. 11 That study used pooled samples from only 2 ICM and 2 NICM patients and likely did not have adequate resolution to detect changes in gene expression. 28 Although the differential gene expression between failing and nonfailing hearts has been attributed to age and gender differences, 13 this analysis has not been extended to ICM and NICM; however, we addressed this possibility by stratifying our analysis by clinical characteristics. The sensitivity and specificity were not affected, which indicates that the accuracy of the etiology prediction profile is not an artifact of differences in baseline characteristics.
The majority of the genes in the etiology prediction profile were not observed in prior microarray analyses. This supports the validity of those studies because they compared failing and nonfailing hearts 9 -13 or hearts after LVAD support, [15] [16] [17] [18] rather than ICM and NICM. The present analysis also focused on prediction and thus targeted different genes than one that investigates differential gene expression. 3 Many of the genes in the etiology prediction profile are not known to be expressed in myocardial tissue. This discrepancy has been observed in prior microarray experiments in cardiomyopathy 9 -18 and stems from the gap between the number of genes on the microarray platform and our ability to define their functions. 29 However, the inability to justify the biological validity of every gene in the profile does not invalidate its clinical utility. In prediction analysis, it is the pattern of gene expression rather than the individual genes themselves that serves as a biomarker of disease. 3, 30, 31 Nevertheless, there is biological plausibility for a number of genes in the prediction profile. The upregulation of signal transduction genes in ischemic hearts, including several protein phosphatases and a mitogen-activate protein kinase, is supported by evidence that their gene products may protect against ischemic injury. [32] [33] [34] The upregulation of endothelin-converting enzyme in ICM over NICM has also been described. 35 One would expect upregulation of genes involved in cell growth/maintenance, including ribosomal and cell division cycle proteins, because the myocyte proliferation rate is higher in ICM than NICM. 36 However, although these findings support the biological validity of the etiology prediction profile, the changes bear further investigation with a study focused on differential gene expression. If confirmed, these genes could provide insight into new cause-specific therapies for heart failure patients.
Gene expression analysis is considered hypothesis generating until validated by another technique. Unlike the majority of studies in cardiology, in which microarray analysis focuses on the discovery of novel genetic pathways, the present analysis concentrates on prediction. Thus, validation involves evaluating the predictive accuracy of the profile in independent, blinded samples. 30, 31, 37 This is an established approach among studies in the cancer literature. [5] [6] [7] However, the level of transcript abundance should also be confirmed with quantitative PCR to determine whether the prediction profile offers utility independent of the microarray platform. We confirmed the expression level of 4 genes in the prediction profile using quantitative PCR, and the fold changes agreed in all cases.
Several methodological aspects of the present study warrant mention. There is little information regarding sample-size requirements in microarray analysis. One study determined that for accurate class prediction of etiology, a training set of 10 to 20 samples is required. 28 Thus, the sample size in the present study was adequate for prediction. We were also able to maximize the amount of information obtained by random partitioning of samples. Furthermore, to the best of our knowledge, the present study includes the largest number of samples in a cardiovascular microarray study to date.
Finally, it may be argued that a gene expression profile that identifies patients on the basis of prognosis would be more clinically valuable than one based on etiology, which is determinable by other methods. The present findings are valuable proof-of-concept that other predictions will be possible in the future. Indeed, the transition from gene profiling of etiology [1] [2] [3] to gene profiling of prognosis 4 -7 represents the path taken in the oncology experience.
The present study represents the first use of gene expression profiling in cardiovascular disease and the first evidence that microarray hybridization from endomyocardial biopsies is feasible. Microarray analysis has the potential to optimize the diagnosis and management of patients with myocardial diseases. These results form the basis for future studies using molecular profiling to distinguish cardiomyopathy patients by other relevant clinical parameters. Studies are currently under way to develop gene expression profiles that distinguish ischemic and nonischemic cardiomyopathy in newly diagnosed patients and to differentiate these patients by prognosis and response to therapy. Table 3 .
